BrainQ
Last updated: May 7, 2026
BrainQ develops AI-guided, non-invasive neuromodulation for stroke recovery and broader neurorehabilitation, with credible adjacency to military traumatic brain injury care.
Visit WebsiteCompany Overview
BrainQ is building a non-invasive neurorehabilitation platform centered on AI-guided electromagnetic stimulation for patients recovering from stroke and related neurological injuries. The company positions the system as a personalized therapy layer: it maps brain activity, identifies the patient-specific recovery state, and then uses targeted stimulation protocols intended to support neuroplasticity and functional recovery.
The homepage and product messaging emphasize stroke recovery and intelligent neurotherapy rather than generic consumer neurotech. That matters because the commercial problem is a large, expensive, and operationally difficult one: rehabilitation teams need interventions that can fit into clinical workflows, be repeatable across patients, and produce measurable motor or functional gains that justify adoption and reimbursement. BrainQ is therefore competing not only on technical novelty, but on whether it can show that a software-informed stimulation protocol reliably improves outcomes in real rehab settings, with enough consistency to matter to clinicians, payers, and hospital administrators.
From a diligence perspective, the most important distinction is that this is not a broad brain-computer-interface platform chasing many endpoints at once. It is a focused therapeutic product category with a narrower initial indication and a clearer regulatory path than many neurotech ventures. That focus can be a strength if the company continues to validate the approach in controlled studies and can translate results into practical deployment in hospitals and rehabilitation centers.
BrainQ's public footprint is still much more like an evidence-building medical company than a mature commercial platform. That is useful context: the key diligence questions are whether it can continue to publish or otherwise demonstrate reproducible clinical benefit, whether the therapy can be implemented without excessive training or equipment burden, and whether the product can earn a durable place in post-acute care pathways rather than remaining a promising but optional adjunct.
Dual-use relevance is credible but should be framed carefully. Stroke recovery is the primary civilian market; defense relevance comes from the overlap with traumatic brain injury, blast exposure, and post-acute neurorehabilitation needs in military medicine. If the therapy proves portable, repeatable, and clinically useful, it could fit into military treatment pipelines and veteran care programs. The strategic question is less whether a defense use case exists and more whether the company can evidence durable clinical benefit, operational simplicity, reimbursement readiness, and enough procedural simplicity to make the platform useful outside specialized research centers.
Dual-Use Assessment
BrainQ's personalized neuromodulation platform has civilian utility in stroke rehabilitation and plausible defense utility in traumatic brain injury and post-blast recovery programs. The dual-use case is strongest where military medicine needs non-invasive, repeatable rehabilitation tools that can be deployed in hospitals or veteran care settings, but it remains contingent on durable clinical effect and operational practicality.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
BrainQ is strategically relevant as a focused deep-tech therapeutics company if the clinical signal continues to hold up, because it targets a large unmet need, has a defensible technical narrative, and offers real dual-use adjacency. The opportunity is attractive because it sits at the intersection of neurotechnology, rehabilitation, and evidence-driven medicine, but it is still contingent on strong evidence, reimbursement progress, workflow adoption, and a credible path from trial results to repeatable clinical use.
Strategic Value to U.S.-Israel Alliance
The strategic value lies in a platform that could help allied medical systems treat stroke and traumatic brain injury with a non-invasive, repeatable therapy. That matters for civilian rehabilitation capacity, where stroke recovery is expensive and labor-intensive, and for defense medicine, where neurological injury is a persistent and operationally costly problem that affects force readiness, long-term care obligations, and veteran outcomes.
Key Technologies
- EEG-based brain-state mapping
- AI-driven patient phenotyping
- Personalized stimulation protocol generation
- Non-invasive electromagnetic neuromodulation
- Neuroplasticity-oriented signal processing
- Clinical workflow software for rehabilitation
Use Cases & Applications
- Post-stroke motor rehabilitation
- Inpatient neurorehabilitation programs
- Outpatient recovery clinics
- Post-acute functional recovery after neurological injury
- Traumatic brain injury rehabilitation
- Military and veteran neurorehabilitation programs
- Translational stroke-recovery research
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- Official website Primary public reference for company identity, positioning, and current web presence.
- Profile update timestamp Last updated in the Claw & Talon database on May 7, 2026.
Investor Lens
What this entry is
Private startup
Why it may matter
BrainQ may matter as a General Technology entry with not currently an investable standalone company for Israeli technology research.
How an independent investor should read this
Not currently an investable standalone company. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify traction
- Verify cap table/funding
- Verify regulatory/export-control issues
- Verify customer concentration
Main investor questions
- Is the company currently active, independently financeable, and raising or not raising on terms you can verify?
- What customer, revenue, product, and technical evidence supports the company story?
- What valuation, cap table, rights, and follow-on assumptions would govern any private exposure?
- Does the dual-use claim map to actual commercial and government/defense/resilience buyer evidence?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies BrainQ's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Where does the product create real defense, intelligence, critical-infrastructure, or emergency-response value beyond ordinary commercial adoption?
- What regulatory, procurement, and buyer-adoption constraints could slow deployment in strategic or government-adjacent markets?
- What would disconfirm the priority signal: weak customer references, thin technical differentiation, poor capital efficiency, or limited allied-market access?
Related sector
See the General Technology sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.